Lee Kalowski Sells 9,072 Shares of Q32 Bio (NASDAQ:QTTB) Stock

by · The Markets Daily

Q32 Bio Inc. (NASDAQ:QTTB – Get Free Report) CFO Lee Kalowski sold 9,072 shares of the firm’s stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $3.46, for a total value of $31,389.12. Following the completion of the sale, the chief financial officer owned 39,938 shares of the company’s stock, valued at $138,185.48. This represents a 18.51% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Q32 Bio Price Performance

Shares of QTTB traded up $0.05 on Thursday, reaching $3.62. 892,817 shares of the stock traded hands, compared to its average volume of 1,268,199. The stock’s 50-day moving average price is $2.61 and its 200-day moving average price is $2.11. The firm has a market cap of $44.54 million, a price-to-earnings ratio of -1.05 and a beta of 0.23. Q32 Bio Inc. has a 12 month low of $1.35 and a 12 month high of $28.06.

Q32 Bio (NASDAQ:QTTB – Get Free Report) last issued its earnings results on Thursday, November 13th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($1.39) by $0.79. As a group, equities research analysts forecast that Q32 Bio Inc. will post -12.32 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Q32 Bio in a research report on Tuesday, October 14th. Wall Street Zen upgraded shares of Q32 Bio from a “sell” rating to a “hold” rating in a research note on Sunday, October 26th. Two equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Q32 Bio has an average rating of “Hold” and a consensus target price of $12.17.

Check Out Our Latest Stock Report on Q32 Bio

Hedge Funds Weigh In On Q32 Bio

Several institutional investors have recently bought and sold shares of QTTB. Marshall Wace LLP bought a new stake in shares of Q32 Bio during the second quarter worth $25,000. Goldman Sachs Group Inc. raised its holdings in shares of Q32 Bio by 140.9% in the first quarter. Goldman Sachs Group Inc. now owns 44,373 shares of the company’s stock valued at $73,000 after buying an additional 25,953 shares during the last quarter. Acadian Asset Management LLC acquired a new position in Q32 Bio during the 1st quarter worth about $50,000. Two Sigma Investments LP bought a new stake in Q32 Bio during the 3rd quarter worth about $62,000. Finally, AQR Capital Management LLC bought a new stake in Q32 Bio during the 1st quarter worth about $68,000. Institutional investors own 31.32% of the company’s stock.

Q32 Bio Company Profile

(Get Free Report)

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.

Further Reading